Approved & therapeutic
Goserelin
Zoladex
Goserelin is a GnRH agonist supplied as a biodegradable implant placed subcutaneously in the abdominal wall. It is approved for prostate cancer, breast cancer, endometriosis and endometrial thinning before ablation.
Also known as: Goserelin acetate
- Status
- Goserelin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 2 to 4 hours for the released peptide; the implant delivers over 28 days or 12 weeks.
- How it's taken
- Subcutaneous implant into the upper abdominal wall
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- GnRH, Androgen, Estrogen
How Goserelin works
As with other GnRH agonists, continuous exposure desensitises pituitary GnRH receptors after an initial gonadotropin surge, suppressing LH and FSH and therefore testosterone or estradiol to castrate or postmenopausal levels.
What research has looked at
- Provides androgen deprivation in advanced prostate cancer, and is also used with radiotherapy in locally advanced disease.
- Used in palliative treatment of advanced breast cancer in pre- and perimenopausal women, and in ovarian suppression strategies.
- The solid implant avoids reconstitution and delivers over 28 days or 12 weeks depending on strength.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Disease flare from the initial gonadotropin surge, with the same cord-compression and ureteric-obstruction concerns as other GnRH agonists in prostate cancer.
- Hot flashes, sweating, decreased libido and erectile dysfunction.
- Decreased bone mineral density with prolonged therapy.
- Injection-site reactions and, rarely, injury during implant insertion.
- Hyperglycemia and increased cardiovascular risk with long-term androgen deprivation.
Sources
- FDA approved-drug listing for goserelin · U.S. Food & Drug Administration
- DailyMed prescribing information for goserelin · NIH · DailyMed
- PubMed research on goserelin prostate breast cancer · NIH · National Library of Medicine
- DrugBank record for goserelin · DrugBank
Track Goserelin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Goserelin FAQ
What is Goserelin?
Goserelin is a GnRH agonist supplied as a biodegradable implant placed subcutaneously in the abdominal wall. It is approved for prostate cancer, breast cancer, endometriosis and endometrial thinning before ablation.
How does Goserelin work?
As with other GnRH agonists, continuous exposure desensitises pituitary GnRH receptors after an initial gonadotropin surge, suppressing LH and FSH and therefore testosterone or estradiol to castrate or postmenopausal levels.
Is Goserelin FDA approved?
Yes. Goserelin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Goserelin?
Reported half-life: Approximately 2 to 4 hours for the released peptide; the implant delivers over 28 days or 12 weeks.
How is Goserelin taken?
Subcutaneous implant into the upper abdominal wall.
What side effects have been reported with Goserelin?
Reported in the sources: Disease flare from the initial gonadotropin surge, with the same cord-compression and ureteric-obstruction concerns as other GnRH agonists in prostate cancer; Hot flashes, sweating, decreased libido and erectile dysfunction; Decreased bone mineral density with prolonged therapy; Injection-site reactions and, rarely, injury during implant insertion; Hyperglycemia and increased cardiovascular risk with long-term androgen deprivation.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.